Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study

Abstract

These data show an increase of new CVD events in the untreated group. Despite the study limitations, SBI seems to be a negative prognostic factor and ASA preventive treatment might improve SBI prognosis. <b>EU Clinical trial</b> is registered with EudraCT Number: 2005-000996-16; Sponsor Protocol Number: 694/30.06.04.